WVE
Neutral signalScored 2026-08-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Wave Life Sciences Ltd.
- Nom
- Wave Life Sciences Ltd.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $626.6M
- Employés
- 317
- PDG
- Paul Bolno
- Site web
- https://wavelifesciences.com
- Marché
- ALNYARCTARWRBNTCIONSNTLA
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 23 996 titres (~135 071,96 $ US)
- Insiders
- Wagner Heidi LRawcliffe AdrianTAKANASHI KENTan Aik Na
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$135,072
Avg sell (VWAP, 90d window) $5.63 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$135,072 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-12 | Rawcliffe Adrian | Sell · S · 10b5-1 | 12,700 | $5.29 | $67,183 | Form 4 |
| 2026-08-11 | TAKANASHI KEN | Sell · S · 10b5-1 | 3,864 | $6.01 | $23,223 | Form 4 |
| 2026-08-11 | Tan Aik Na | Sell · S · 10b5-1 | 432 | $6.01 | $2,596 | Form 4 |
| 2026-08-11 | Wagner Heidi L | Sell · S · 10b5-1 | 7,000 | $6.01 | $42,070 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
WVE presents a high-risk, speculative setup: strong liquidity (score 85) provides a short-term runway, but catastrophic fundamental trends (score 25, -478% net margin, negative OCF) signal no near-term path to…
The first sentence of the analysis written for WVE on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $135K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $135K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 6.47 · operating margin -504% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -478.3% | -89.6% | -51.4% | -4416.1% | -298.9% | |
| Ebitda Margin | -457.6% | -81.6% | -43.2% | -4138.9% | -274.9% | |
| Operating Profit Margin | -504.1% | -101.9% | -60.0% | -4459.3% | -310.1% | |
| Pretax Profit Margin | -478.3% | -89.6% | -51.4% | -4416.1% | -298.9% | |
| Continuous Operations Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Net Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Bottom Line Profit Margin | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | |
| Current Ratio | 6.467 | 2.888 | 1.262 | 1.378 | 2.532 | |
| Quick Ratio | 6.467 | 2.888 | 1.262 | 1.378 | 2.532 | |
| Solvency Ratio | -1.742 | -0.619 | -0.205 | -0.792 | -0.644 | |
| Cash Ratio | 6.333 | 2.723 | 1.075 | 1.237 | 2.345 | |
| Price To Earnings Ratio | -14.050 | -17.671 | -9.352 | -3.415 | -1.331 | |
| Price To Earnings Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Forward Price To Earnings Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Price To Earnings Diluted Ratio | -14.050 | -17.671 | -9.352 | -3.415 | -1.331 | |
| Price To Earnings Diluted Growth Ratio | -0.193 | -0.596 | 0.127 | 0.260 | 0.035 | |
| Price To Book Ratio | 5.448 | 8.164 | 13.520 | -12.242 | 5.007 | |
| Price To Sales Ratio | 67.102 | 15.794 | 4.729 | 151.272 | 3.973 | |
| Price To Free Cash Flow Ratio | -15.291 | -11.256 | -26.078 | -4.274 | -1.817 | |
| Price To Operating Cash Flow Ratio | -15.291 | -11.326 | -27.574 | -4.320 | -1.829 | |
| Debt To Assets Ratio | 0.028 | 0.072 | 0.117 | 0.257 | 0.145 | |
| Debt To Equity Ratio | 0.034 | 0.121 | 0.810 | -0.834 | 0.921 | |
| Debt To Capital Ratio | 0.033 | 0.108 | 0.448 | -5.031 | 0.479 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.213 | 1.681 | 6.938 | -3.246 | 6.370 | |
| Working Capital Turnover Ratio | 0.117 | 0.838 | 2.984 | 0.058 | 0.395 | |
| Operating Cash Flow Ratio | -1.972 | -1.361 | -0.104 | -1.787 | -1.386 | |
| Operating Cash Flow Sales Ratio | -4.388 | -1.394 | -0.171 | -35.018 | -2.172 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.006 | 1.057 | 1.011 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.553 | -5.945 | -0.605 | -3.397 | -2.975 | |
| Capital Expenditure Coverage Ratio | -261.132 | -161.009 | -17.427 | -93.888 | -158.916 | |
| Dividend Paid And Capex Coverage Ratio | -261.132 | -161.009 | -17.427 | -93.888 | -158.916 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.675 | -16.230 | -7.504 | -3.318 | -0.374 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.3% | ▼-20.7% | ▼-16.6% |
| Ebit Margin | -478.3% | ▼-388.8% | ▲588.5% |
| Ebitda Margin | -457.6% | ▼-376.0% | ▲541.6% |
| Operating Profit Margin | -504.1% | ▼-402.1% | ▲583.0% |
| Pretax Profit Margin | -478.3% | ▼-388.8% | ▲588.5% |
| Continuous Operations Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Net Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Bottom Line Profit Margin | -478.3% | ▼-388.8% | ▲592.0% |
| Current Ratio | 6.467 | ▲3.580 | ▲3.562 |
| Quick Ratio | 6.467 | ▲3.580 | ▲3.562 |
| Solvency Ratio | -1.742 | ▼-1.123 | ▼-0.941 |
| Cash Ratio | 6.333 | ▲3.611 | ▲3.591 |
| Price To Earnings Ratio | -14.050 | ▲3.622 | ▼-4.886 |
| Price To Earnings Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Forward Price To Earnings Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Price To Earnings Diluted Ratio | -14.050 | ▲3.622 | ▼-4.886 |
| Price To Earnings Diluted Growth Ratio | -0.193 | ▲0.404 | ▼-0.119 |
| Price To Book Ratio | 5.448 | ▼-2.716 | ▲1.469 |
| Price To Sales Ratio | 67.102 | ▲51.308 | ▲18.528 |
| Price To Free Cash Flow Ratio | -15.291 | ▼-4.036 | ▼-3.548 |
| Price To Operating Cash Flow Ratio | -15.291 | ▼-3.966 | ▼-3.224 |
| Debt To Assets Ratio | 0.028 | ▼-0.044 | ▼-0.096 |
| Debt To Equity Ratio | 0.034 | ▼-0.087 | ▼-0.177 |
| Debt To Capital Ratio | 0.033 | ▼-0.075 | ▲0.825 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.213 | ▼-0.468 | ▼-1.378 |
| Working Capital Turnover Ratio | 0.117 | ▼-0.721 | ▼-0.761 |
| Operating Cash Flow Ratio | -1.972 | ▼-0.611 | ▼-0.650 |
| Operating Cash Flow Sales Ratio | -4.388 | ▼-2.994 | ▲4.241 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.006 | ▼-0.016 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -10.553 | ▼-4.609 | ▼-5.858 |
| Capital Expenditure Coverage Ratio | -261.132 | ▼-100.124 | ▼-122.658 |
| Dividend Paid And Capex Coverage Ratio | -261.132 | ▼-100.124 | ▼-122.658 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.675 | ▲4.555 | ▼-3.855 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.87B | $1.71B | $535.8M | $552.0M | $162.7M | |
| Enterprise value | $2.28B | $1.43B | $367.6M | $501.1M | $42.1M | |
| EV / Sales | 53.43x | 13.24x | 3.24x | 137.33x | 1.03x | |
| EV / Op. cash flow | -12.18x | -9.49x | -18.92x | -3.92x | -0.47x | |
| EV / Free cash flow | -12.18x | -9.44x | -17.89x | -3.88x | -0.47x | |
| EV / EBITDA | -11.68x | -16.23x | -7.50x | -3.32x | -0.37x | |
| Net debt / EBITDA | 2.99x | 3.13x | 3.43x | 0.34x | 1.07x | |
| Current ratio | 6.47x | 2.89x | 1.26x | 1.38x | 2.53x | |
| Income quality | 0.92x | 1.56x | 0.34x | 0.79x | 0.73x | |
| Graham net-net | $3 | $1 | -$0 | -$1 | -$0 | |
| Tax burden | 100.0% | 100.0% | 98.8% | 100.4% | 99.8% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $519.7M | $209.4M | $48.9M | $27.0M | $98.4M | |
| Invested capital | $539.6M | $237.4M | $84.7M | $71.1M | $139.0M | |
| Return on assets | -32.0% | -27.5% | -20.9% | -110.5% | -59.1% | |
| Operating ROA | -43.5% | -35.2% | -32.3% | -92.1% | -52.2% | |
| Return on tangible assets | -32.0% | -27.5% | -20.9% | -110.5% | -59.1% | |
| Return on equity | -38.8% | -46.3% | -145.1% | 358.9% | -376.2% | |
| Return on invested capital | -39.0% | -44.4% | -70.6% | -202.5% | -85.8% | |
| Return on capital employed | -39.6% | -45.8% | -76.8% | -217.4% | -88.9% | |
| Earnings yield | -7.1% | -5.7% | -10.7% | -29.3% | -75.1% | |
| Free cash flow yield | -6.5% | -8.9% | -3.8% | -23.4% | -55.0% | |
| Capex / Op. cash flow | -0.4% | -0.6% | -5.7% | -1.1% | -0.6% | |
| Capex / Depreciation | 8.1% | 10.8% | 12.1% | 13.5% | 5.7% | |
| Capex / Sales | 1.7% | 0.9% | 1.0% | 37.3% | 1.4% | |
| SG&A / Sales | 176.3% | 54.5% | 45.3% | 1384.3% | 112.6% | |
| R&D / Sales | 427.8% | 147.4% | 114.7% | 3175.0% | 297.5% | |
| Stock comp / Sales | 0.0% | 12.1% | 8.6% | 471.2% | 40.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 11d | 5d | 68d | 0d | 0d | |
| Days payables outstanding | 647d | 0d | 0d | 0d | 0d | |
| Operating cycle | 11d | 5d | 68d | 0d | 0d | |
| Cash conversion cycle | -636d | 5d | 68d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
- 2026-08-11 Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
- 2026-08-10 Wave Life Sciences Announces Completion of Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).
- 2026-08-05 Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
- 2026-08-04 Wave Life Sciences to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave''s management team are scheduled to participate in two upcoming investor conferences in August.
- 2026-07-30 WAVE Life Sciences Q2 Earnings Call Highlights WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.
- 2026-07-30 Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
- 2026-07-30 Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
- 2026-07-30 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007''s potential in MASH, type 2 diabetes, and other cardiometabolic diseases
- 2026-07-23 Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company''s second quarter 2026 financial results and provide business updates.